Anti-CD19 CAR Lentivirus (CD19 ScFv-CD8-4-1BB-CD3zeta; SIN Vector)

Mfr.No.

78601

Description

The anti-CD19 CAR lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce most mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv portion of anti-CD19 (clone FMC63) linked to 2nd generation CAR (Chimeric Antigen Receptor), containing CD8 hinge, 4-1BB and CD3ζ signaling domains.

Note: This product transduces the same anti-CD19 CAR construct (CD19 ScFv-CD8-4-1BB-CD3ζ) as other available anti-CD19 CAR Lentiviruses (BPS Bioscience # 78600, 78602 and 78775), but differ in key aspects. Please see the table below.

Product SKU	Self-Inactivation (SIN)	Selection Marker
BHV18200003	no	puromycin
BHV18200006	yes	no
BHV18200004	yes	puromycin
BHV18200005	yes	eGFP

CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy.

The lentiviruses were produced from HEK293T cells, concentrated, and resuspended in DMEM. Virus particles can be packaged in custom formulations by special request, for an additional fee.

Biosafety
The lentiviruses are produced with the third generation SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS Bioscience recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.

Applications Range

Positive control for anti-CD19 CAR evaluation in T cells.
Transduction optimization experiments.
Generate anti-CD19 CAR-T cells (for research use only, not for therapeutic purposes).

Storage

Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the virus at -80°C.

Shipping

-80°C